潜入机械臂赛道，节卡机器人还在等上市

Core Viewpoint - The company, Jieka Robotics, is preparing for its IPO on the Sci-Tech Innovation Board, having submitted its prospectus and updated its financial performance for 2024, showing a shift towards humanoid robotic arms amidst a growing market trend for such products [1][5]. Financial Performance - Revenue projections for Jieka from 2022 to 2024 are 281 million yuan, 350 million yuan, and 400 million yuan respectively, with net profits of 5.74 million yuan in 2022 and 6.23 million yuan in 2024, while incurring a net loss of 28.55 million yuan in 2023 [1]. - Revenue from robotic systems is expected to grow significantly, with projections of 216 million yuan, 256 million yuan, and 374 million yuan for the same period, representing 77.24%, 73.23%, and 93.63% of total revenue respectively [4]. Product Development and Market Position - Jieka has focused on collaborative robots, which are lighter and do not require safety barriers, making them suitable for various production and service scenarios [3]. - The company has also entered the humanoid robot market with its K series, having sold 348 units of humanoid robotic arms in 2024, contributing to its overall robotic systems revenue [5][7]. - The Zu series is the main revenue driver, contributing 55.23% to the robotic systems revenue in 2024, followed by the C series at 11.41% and the Pro series at 8.06% [5]. Competitive Landscape - The global market for collaborative robots is competitive, with major players including Danish company Universal Robots and Japanese company Fanuc, alongside domestic competitors like Aobo and Ailite [9]. - Jieka's market share is not dominant, and it faces significant competition from established brands like ABB and KUKA, which hold over 50% of the market [9]. Strategic Challenges and Opportunities - The rise of humanoid robots presents both opportunities and challenges for Jieka, as it must navigate increased competition while leveraging its technological advancements in robotic arms [7][8]. - The company’s reliance on a single product segment could pose risks, as the integration capabilities required for humanoid robots are higher [8]. Financial Health Indicators - Jieka's accounts receivable as a percentage of revenue has increased from 20.75% in 2022 to 40.84% in 2024, indicating potential cash flow concerns [10]. - The company’s reliance on government subsidies and the health of its cash flow are critical areas to monitor, despite revenue growth [10].